CNRS Press l Véronique Etienne l T +33 (0)1 44 96 51 37 l firstname.lastname@example.org
A veritable sensor: a team of Inserm and CNRS researchers at the Institute of Pharmacology and Structural Biology (IPBS, CNRS/Paul Sabatier University – Toulouse III) has identified a protein that is able to detect various allergens in the respiratory tract, which are responsible for asthma attacks. This study, co-led by Corinne Cayrol and Jean-Philippe Girard, was published in Nature Immunology on March 19, 2018. It offers hope for breakthroughs in the treatment of allergic illnesses.
What do mold, pollen and cockroaches have in common? Although they belong to three distinct kingdoms of the living world, they can all trigger asthma attacks in people sensitive to them. And all of them, despite their very different compositions, contain enzymes called proteases.
The IPBS team has identified a human protein that reacts to a large number of environmental allergens: interleukin-33 (IL-33). When they enter the human respiratory tract, the allergens release their proteases. These split the IL-33 into extremely reactive fragments which trigger the chain reactions behind allergy symptoms.
This appears to be a general mechanism responsible for triggering allergic reactions. Indeed, IL-33 was shown to detect each of the 14 allergens tested, some of which are present in ambient air (several types of pollen, house dust mites, fungal spores) and others implicated in occupational asthma (such as subtilisin, found in detergents).
Furthermore, clinical trials now under way are focusing on this protein. And they are on the right track, given this recent discovery of a single mechanism for detection of airborne allergens by IL-33. Inhibiting the production of reactive IL-33 fragments following allergen exposure could, for example, limit severe allergic reactions in asthmatic patients.
Mucous production in the lung following inhalation of an allergen : IL-33 sensor present (left), IL-33 sensor deactivated (right) (lung sections, mucous shown in magenta).
Excessive mucous production is characteristic of allergic asthma. Protein IL-33, a major factor predisposing humans to asthma, detects allergen protease activity. Activated by proteases, IL-33 sets off a cascade of reactions, including mucus production, that are associated with asthma and other allergic illnesses. When IL-33 activation is inhibited (on the right), these reactions are not triggered.
© Corinne Cayrol and Jean-Philippe Girard / IPBS / CNRS-Paul Sabatier University – Toulouse III
Monoclonal antibody therapy can be very effective in treating numerous illnesses, such as cancers, chronic inflammatory conditions, and infectious diseases. Researchers from Inserm, Université de Paris, Sorbonne Université and CNRS1 have designed and tested a new immunotherapy approach that uses pre-existing antibodies ...
In a new study, researchers from Inserm and Université de Bordeaux at the Bordeaux Population Health Research Center, in collaboration with the Research Institute for Sustainable Development (IRD) and the NGO ALIMA (The Alliance for International Medical Action), have developed and tested ...
Environmental allergens induce allergic inflammation through proteolytic maturation of IL-33. Corinne Cayrol*, Anais Duval*, Pauline Schmitt, Stephane Roga, Mylène Camus, Alexandre Stella, Odile Burlet-Schiltz, Anne Gonzalez-de-Peredo and Jean-Philippe Girard. Nature Immunology, March 19, 2018. DOI: http://dx.doi.org/10.1038/s41590-018-0067-5